Has Joseph Liberman, MD received payments from drug or device companies?

Yes. Drug and device makers reported $9,495 in general payments to Joseph Liberman, MD across 474 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Joseph Liberman, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Joseph Liberman, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Joseph Liberman, MD

Neurology · Washington, DCNPI 1871532069

Payments from drug & device makers

$9,495in general payments, 2019–2025

Across 474 payments — averaging $20.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Biogen$1K
Novartis$1K
AbbVie$969
Sunovion Pharmaceuticals Inc.$892
Teva Pharmaceuticals USA, Inc.$750
Sumitomo Pharma America, Inc.$487
plus $4K from 34 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Biogen	52	$1,052
Novartis	48	$1,002
AbbVie(2 entities)	49	$969
Sunovion Pharmaceuticals Inc.	60	$892
Teva Pharmaceuticals USA, Inc.	40	$750
Sumitomo Pharma America, Inc.	23	$487
Sanofi	22	$429
UCB, Inc.	21	$405
Lilly USA, LLC	20	$387
Bristol Myers Squibb	12	$305
Genentech USA, Inc.	20	$292
Revance Therapeutics, Inc.	3	$290
EMD Serono, Inc.	16	$271
Eisai Inc.	10	$227
Amgen	8	$185
TG Therapeutics, Inc.	2	$170
Lundbeck LLC	7	$170
Alnylam Pharmaceuticals Inc.	7	$146
E.r. Squibb & Sons, L.L.C.	6	$115
Catalyst Pharmaceuticals, Inc.	4	$96
Biohaven Pharmaceuticals, Inc.	4	$83
Scilex Pharmaceuticals Inc.	5	$78
AstraZeneca	4	$77
Upsher-smith Laboratories LLC	3	$67
Neurocrine Biosciences, Inc.	3	$61
Almatica Pharma LLC	3	$57
Axsome Therapeutics, Inc.	2	$50
Johnson & Johnson	2	$48
Supernus Pharmaceuticals, Inc.	2	$46
Vertical Pharmaceuticals, LLC	3	$45
Acorda Therapeutics, Inc	2	$40
Bausch Health US, LLC	2	$40
Pfizer	2	$38
Natus Medical Incorporated	1	$21
Mallinckrodt Hospital Products Inc.	1	$19
Mallinckrodt Enterprises LLC	1	$19
Adamas Pharmaceuticals, Inc.	1	$18
Avion Pharmaceuticals	1	$17
Promius Pharma LLC	1	$17
Biohaven Pharmaceutical Holding Company Ltd.	1	$14

How this compares

$9,495 in reported general payments places this provider in the 65th percentile of 113 neurology providers in District of Columbia.

See all neurology providers in District of Columbia →

Medicare billing

Part B allowed, 2024

$140,114

Medicare patients

258

Services billed

687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Washington

Raymond TurnerWashington$16.6M
Faria AmjadWashington$4M
Fernando PaganWashington$3.7M
Laxman BahrooWashington$3.1M
Fahd AmjadWashington$2.9M
Brian BarryWashington$1.5M
Benjamin OsborneWashington$1.5M
Jessica AilaniWashington$1.5M
Yasar Torres-YaghiWashington$1M
Carlo TornatoreWashington$870K

See the full list for District of Columbia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →